Kommandantvold, Svenn Alexander
Chang, Shih-Chen
Surinach, Andy
Yau, Vincent
Best, Jennie H.
Zaraket, Hassan
Zhou, Hao
Frimpter, Jeff
Blanchet Zumofen, Marie-Helene
Funding for this research was provided by:
Genentech
Article History
Received: 17 May 2024
Accepted: 30 July 2024
First Online: 16 August 2024
Declarations
:
: Svenn Alexander Kommandantvold: Employee and shareholder of Roche Norge AS. Shih-Chen Chang: Employee and shareholder of Genentech Inc, a member of the Roche Group. Andy Surinach: Employee of Genesis Research, which received funding for this study from Genentech Inc, a member of the Roche Group. Vince Yau: Employee and shareholder of Genentech Inc, a member of the Roche Group. Jennie H. Best: Employee and shareholder of Genentech Inc, a member of the Roche Group. Hassan Zaraket: Employee and shareholder of Roche Products Ltd. Hao Zhou: Employee and shareholder of Genentech Inc, a member of the Roche Group. Marie-Helene Blanchet Zumofen: Employee and shareholder of F. Hoffmann-La Roche, Ltd.
: This cost-effectiveness model was conducted based on analyses of a secondary-use database and did not recruit any human participants or involve animals.